severe fibrosis was detected in acute Hyal2 KO but not non-acute Hyal2 KO or control mice. Total serum and heart HA levels, as well as size, were increased in acute and non-acute Hyal2 KOs compared to control mice. These findings indicate HYAL2 is essential for the breakdown of extracellular HA. In its absence, extracellular HA accumulates and in some cases can lead to cardio-pulmonary dysfunction. Alterations in HYAL2 function should be considered as a potential contributor to cardiac pathologies in humans.
Hyaluronidase (HYAL) 1 2 is a glycophosphatidylinositol-linked protein and a member of the hyaluronoglucosaminidase family (1, 2) . It is proposed to initiate the degradation of hyaluronan (HA), an abundant glycosaminoglycan (GAG) in the extracellular matrix (ECM) of many vertebrate tissues including heart valves, vitreous of the eye, and synovial fluid. The viscoelastic properties of HA influence the properties of the ECM and are important for cell proliferation, differentiation and migration. A role for HA in embryogenesis has been established using HA synthase 2-deficient mice which die at embryonic day 9.5 due to loss of endocardial cushion swelling and a lack of epithelial to mesenchymal transition (3) .
Regulation of HA levels is required for normal development, and to maintain normal tissue homeostasis. Degradation of HA by HYALs is important to maintaining these levels. Six HYALencoding genes have been identified which are grouped into two tightly linked triplets, one on human chromosome 3p21.3 (HYAL1, HYAL2, HYAL3) and a second on human chromosome 7q31.3 (HYALP1, HYAL4, SPAM1) (4) . With the exception of HYAL4 and HYALP1, all the HYALs are thought to be capable of degrading HA. A role for HYAL1 and HYAL2 in HA degradation in somatic cells has been proposed. In this model, HYAL2 initiates HA degradation into small fragments that are endocytosed and degraded in lysosomes by HYAL1 and exoglycosidases (5, 6) . HYAL2 is a GPI-anchored protein (2) that could act at low pH at the cell surface (7) . It has been suggested that HYAL2 resides in lysosomes in some cell types (8) . Despite the proposed role for HYAL2 in HA degradation, only a deficiency of HYAL1 has been found to cause a human disorder. It causes mucopolysaccharidosis (MPS) IX, a lysosomal storage disorder characterized by joint abnormalities due to HA accumulation (9, 10) .
In the heart valves, GAGs are abundant and play important roles in both developing and mature valves (11, 12) . It is not surprising that cardiovascular manifestations are a prominent feature of many forms of MPS that result from GAG accumulation (13) . For example, mitral valve thickening and stenosis are found in Hurler and Scheie diseases, and these findings are also reflected in the corresponding mouse model (14) . Therefore, defects in ECM modifying enzymes are among the many causes of cardiovascular disease.
HA is one of the major GAGs in the heart valves. Surprisingly, no broad spectrum HA accumulation, including in the heart, was identified during the characterization of Hyal1-, Hyal2-, or Hyal3-deficient mice (15) (16) (17) . Previous studies of Hyal2 -/-(KO) mice revealed craniofacial abnormalities and chronic anemia, as well as unexplained pre-weaning lethality (16) . However, in addition to these features, on an outbred background (C129;CD1;C57BL/6), we have found a gross enlargement of either the left or right atrium in more than half of the Hyal2 KO mice that survived to weaning. Since HA synthesis is known to be essential for normal heart development, we hypothesized that a failure to degrade HA in these mice had resulted in HA accumulation, leading to cardio-pulmonary dysfunction, and premature death.
EXPERIMENTAL PROCEDURES
Generation of Hyal2 KO Mice: Hyal2 KO mice were generated as part of a previous study (16) . For the current study, Hyal2 KO mice and littermate controls, either wild type (+/+) or heterozygous (+/-), on an outbred background (C129;CD1;C57BL/6) were derived through breeding of Hyal2 heterozygotes. Mice were genotyped using PCR-based strategies on DNA samples isolated from ear punches. For the amplification of wild type Hyal2 and the Neotargeted Hyal2 allele we used the forward and reverse primers (5'-actcagctgctggttcccta-3'; 5'-atagcactggcagcgaaagt-3'), and (5'-aaggaacatcagggaagatcat-3'; 5'-cggtgcccgagactaagtc-3'), respectively. All animal procedures were conducted under protocols approved by the University of Manitoba Animal Hyaluronidase 2 deficiency causes cardiac dysfunction Care Committee and following the guidelines of the Canadian Council on Animal Care.
Histology: Mice were sacrificed by carbon dioxide inhalation and tissues for light microscopy were immediately collected and fixed overnight in either formalin or 10% buffered formalin (Protocol) containing 1% hexadecylpyridinium chloride monohydrate. Tissues for subsequent biochemical studies were stored at -80 o C. Fixed tissues were embedded in paraffin, and 5 µm sections were stained for morphological analysis using established methods for hematoxylin and eosin (18) or for GAG detection using alcian blue (19) , with minor modifications in the time of incubation with the stain. Counter staining for alcian blue was performed with Nuclear Fast Red (ScyTek Laboratories) for 2.5 min. Heart and lung ECM was stained using Masson's trichrome stain (Sigma-Aldrich) according to the manufacturer's protocol. Slides were dehydrated, mounted and visualised using bright field microscopy. For the analysis of hypertrophy in cardiomyocytes, slides were incubated for 30 min with 4 µg/ml wheat germ agglutinin (Alexa Fluor ® 488 conjugate), mounted using Prolong Gold (Invitrogen) and visualised by fluorescence microscopy. The area of the cardiomyocytes, as defined by WGA, was measured using AxioVision 4.5 software. A minimum of 7 fields, containing an average of 8 cells per field, were examined for each animal.
Electron microscopy: The valve and surrounding myocardium were collected by punch biopsy from a whole heart that was sliced using a Rodent Heart Slicer Matrix (Zivic Instruments). Tissues were fixed for 4 h at room temperature in 2% glutaraldehyde, 2% paraformaldehyde prepared in 100 mM sodium cacodylate buffer, pH 7.2, containing 10 mM calcium chloride (CaCl 2 ) and 0.7% ruthenium red. After fixation, tissues were washed with wash buffer (100 mM sodium cacodylate, 10 mM CaCl2, 0.7% ruthenium red, 0.7% sucrose, pH 7.2.) for 5 min, 30 min and 1 h at room temperature. Tissues were post-fixed for 1 h in 100 mM sodium cacodylate containing 1% osmium tetroxide and 0.7% ruthenium red followed by three 10 min wash in ddH2O. Tissues were dehydrated for 10 min each in 50% ethanol, 75% ethanol, 95% ethanol, 2 changes in 100% ethanol followed by 100% methanol, and 3 changes in propylene oxide. (17), except without enzyme retrieval and using HABP (1.67 µg/ml for heart and 6.68 µg/ml for lungs) in Trisbuffered saline (pH 7.5) overnight at 4 o C. Sections were incubated with avidin-conjugated horse radish peroxidise, detected with diaminobenzidine (DAB), and counter stained in Nuclear Fast Red. To verify the specificity of the HABP, sections were incubated overnight with 25 U/ml hyaluronidase from Streptomyces hyalurolyticus (Sigma) before the HABP detection.
C.
For the detection of α-SMA, F4/80, and CD31, the sections were incubated overnight at 4 o C with mouse monoclonal anti-human smooth muscle actin (1:300, Dako Denmark), rat monoclonal anti-mouse F4/80 (1:100, AbD Serotec), or rabbit polyclonal anti-CD31 (1:50, Abcam), respectively. Secondary antibodies, biotinylated rabbit anti-mouse (1:1000, Dako Denmark), or goat anti-rat (1:500, Invitrogen), were used to detect the primary complexes, and complex detection was as for HA, above. For F4/80 and CD31, antigen retrieval was performed by incubating the slides for 20 min at 95 o C in 10 mM sodium citrate (pH 6).
Analysis of HA concentration and sizes: Blood was collected from mice immediately following euthanasia or from the saphenous vein of living mice at 6 and 12 weeks. Serum was collected from clotted blood by centrifugation at 3000 rpm for 10 min and stored at -80 o C. HA levels were quantified using an ELISA-like HA test plate (R&D System) according to the manufacturer. All samples were analyzed in duplicate and the average value was used for subsequent comparisons.
Fluorophore assisted carbohydrate electrophoresis (FACE) was performed for quantification of HA and chondroitin sulphate in Hyaluronidase 2 deficiency causes cardiac dysfunction tissues (20) . Briefly, GAGs isolated from frozen heart tissue using 50 µg/µl proteinase K digestion and ethanol precipitation, were cleaved to disaccharide units by overnight incubation in hyaluronidase SD (Seikagaku Cat# 100741-1) or chondroitinase ABC (Sigma-Aldrich) in 200 mM ammonium acetate. The disaccharides were isolated, labelled with 2-aminoacridone, and quantified in comparison to known disaccharide standards as described previously (21) . The fluorescence was detected using the Fluor-S Max MultiImager (Bio-Rad) and quantified using Quantity One 4.6.9 software (Bio-Rad).
For sizing of HA, GAGs were prepared from tissue (10-15 mg) or serum (200-400 µl) as if for FACE, except 5 mM deferoxamine was included in the proteinase K digestion, and a 4 h incubation at 37 o C with 10 U of DNAse I, and 50 µg of RNAse A was incorporated after destroying the proteinase K by boiling. Instead of digesting the GAGs to disaccharides, they were enriched by precipitating with 1% hexadecylpyridinium chloride monohydrate, as described previously (22) . The pellet was then resuspended in 100 µl of 20 mM Tris pH 8.0, and Pronase was added to 0.2 mg/ml. Following overnight incubation, the GAGs were precipitated with 900 µl of 100% ethanol. The final pellet was resuspended in 15 µl of water; 3 µl of Orange G tracking dye was added and the sample was separated by electrophoresis on a 0.8% agarose gel prepared in Tris-acetate buffer (pH 8.3). The gel was stained overnight with 0.005% Stains-all prepared in 50% ethanol, destained with 10% ethanol until the bands were clearly visible, and photographed. Negative control samples to verify the identity of the HA were prepared by incubating the GAGs overnight with 2.5 U of Hyaluronidase SD before they were analyzed by electrophoresis.
Statistical analysis: The genotype distributions were compared to expected Mendelian ratios using the chi-square test. For all other statistical analysis, data are presented as mean ± SEM. Means were compared by student's t test. P ≤0.05 was considered statistically significant.
RESULTS
Increased mortality in Hyal2 KO mice-We obtained viable Hyal2 KO mice by inter-crossing Hyal2 heterozygotes (+/-), although as reported previously (16), pre-weaning lethality was observed. In fact, only ~9% (70 of 789) of the offspring were Hyal2 KOs at weaning instead of the expected Mendelian 25% (χ 2 (2) = 109.86; p<0.001). Of the viable Hyal2 KO mice, 54% were smaller in size than their littermates, and exhibited rapid onset lethargy, weight loss, dull coat, and shortness of breath requiring euthanasia at an average of 3.2 months of age. Upon dissection, the left or right atrium of these mice was grossly dilated (Fig. 1) . The remaining 46% of Hyal2 KO mice developed a slower onset lethargy, loss of weight, and poor grooming that required euthanasia at an average of 5.8 months of age. Severe atrial dilation was not found in these mice, or in control (Hyal2
However, one kidney was found to be missing in 1% of control mice and 43% (N=29) of Hyal2 KO mice, suggesting this phenotype is increased by Hyal2-deficiency. The kidney phenotype was not further investigated as it was found to be independent of the atrial dilation. For the studies described herein, the Hyal2 KO mice were divided into two categories; mice with atrial dilation were defined as 'acute' and those without atrial dilation were defined as 'non-acute'.
Heart valve expansion in Hyal2 KO mice-The atrial dilation in the acute Hyal2 KO mice, together with the knowledge that HA is abundant in the heart valve, led us to look for a valve abnormality in the Hyal2 KO mice. H & E staining revealed a profound expansion of the pulmonary, mitral, aortic, and tricuspid valves in all mice that were examined (n=9) compared to control littermates (n=7). Representative sections of the pulmonary and mitral valves are presented in Fig.  2 , A-D. To determine if there was any difference in the expansion of the valves in the acute and non-acute Hyal2 KO mice, we compared the expansion/length of the valve leaflet/cups by determining the number of serial sections that included each valve. The valve thickness was significantly greater in Hyal2 KO mice than controls, but there was no significant difference between acute and non-acute Hyal2 KO mice (Fig.  2E) .
Structure/organization of the valves in Hyal2 KO mice-To determine if HA was accumulating in the Hyal2 KO mice, we used the HABP to detect HA. Abundant HA was found throughout the valves (Fig. 3, A-J) , and given the expanded Hyaluronidase 2 deficiency causes cardiac dysfunction size of the valves in the Hyal2 KO, this indicates HA was accumulating in the Hyal2 KO valves.
To determine if the accumulating HA was altering the organization of the ECM of the valve, we examined ECM components using Masson's trichrome staining. Compared to normal valves (Fig. 4B) , those from Hyal2 KO mice were disorganized, with GAGs (non-stained material) deposited between the collagen fibres in the fibrosa and ventricularis/atrialis layers respectively, and resulting in an expanded spongiosa layer (Fig. 4 A) . Endothelial cells in the valve were identified by staining for the endothelial marker CD31. The CD31 positive cells (brown) appeared less frequent in the Hyal2 KO valve, probably because these cells were stretched over the extended surface area of the expanded valve (Fig. 4, C and D) . These findings indicate that the accumulated HA in the ECM of Hyal2 KO mice leads to the expansion, thickening, and disorganization of the valve leaflet/cups.
We also examined the structure of the atrial and ventricular myocardium of acute and nonacute Hyal2 KO mice and controls for additional pathologies. Staining for total GAG with alcian blue revealed accumulation of interstitial GAGs between the atrial cardiac myocytes (Fig. 5 , A, C and E). This staining was more prominent in the acute Hyal2 KO mice than the non-acute Hyal2 KOs, and was always stronger in Hyal2 KO mice than controls, indicating that GAGs were accumulating in the KO mice. In adjacent serial sections, HA was found to be abundant in the ECM of the acute mice compared to both nonacute and control mice (Fig. 5, B, D and F) , providing further evidence that HA is accumulating in the Hyal2 KO mice.
Cardiac hypertrophy in Hyal2 KO mice-To determine if there were additional abnormalities in the cardiac myocytes of Hyal2 KO mice, sections were stained with fluorescently labelled wheat germ agglutinin, and the sizes of the cardiomyocytes were determined. Significant cardiac hypertrophy was found in the upper ventricular region, close to the base of the heart, of acute Hyal2 KO mice compared to controls (Fig.  6A ), but this hypertrophy did not reach significance in the lower ventricular region of acute Hyal2 KO mice (Fig. 6B) , or in non-acute Hyal2 KO mice (Fig. 6, C and D) .
Accumulation of ECM in Hyal2 KO hearts-To further characterize the changes in the Hyal2 KO hearts, we performed transmission electron microscopy on the valves as well as ventricular and atrial myocardium. In the control valves (Fig.  7E) , the ECM was densely packed with collagen fibrils, whereas in the Hyal2 KO valves (Fig. 7A ) ECM separated the collagen fibrils. The accumulated material in the Hyal2 KO valves was clearly extracellular, and was presumed to be HA. The atrial myocardium of Hyal2 KO mice (Fig. 7 , B and C) contained cardiomyocytes which showed a disorganized arrangement of myofibrils and mitochondria and a substantial reduction in myofibrils. In contrast, the atrial cardiomyocytes of control mice showed a sarcoplasm with tightly packed myofibrils and mitochondria (Fig. 7, F and  G) . Within the ventricular myocardium, we observed cardiomyocytes with a disorganized arrangement of myofibrils and mitochondria and a more loosely packed sarcoplasm (Fig. 7D ) when compared to controls (Fig. 7H) Histopathology of lungs in Hyal2 KO mice-To look for additional differences in acute, non-acute and control mice that might be related to atrial dilation, we examined the lungs. A dramatic difference between the acute and non-acute Hyal2 KO lungs was identified. The alveoli were reduced and the alveolar septa thickened in the acute Hyal2 KO mice compared to non-acute and control mice (Fig. 8, A-C) . Further, Masson's trichrome staining revealed increased collagen in the alveolar septae of the acute mice that was absent in both nonacute and control mice (Fig. 8, D-F) . Further investigation of the thickened alveolar septa using anti-α-SMA immunostaining revealed a strong signal for α-SMA in the alveolar interstitium of acute mice which was not detected in the lungs of the non-acute or control mice (Fig. 8, G-I) . Increased levels of HA were also detected in the lungs of acute and non-acute Hyal2 KO compared to control mice (Fig. 8, J-L) although the levels were much higher in the acutely affected animals. Therefore pathology typical of severe pulmonary fibrosis was present only in the acute Hyal2 KO mice. Compared to control mice we observed numerous alveolar macrophages (foam cells) in the inter-and intra-alveolar spaces of acute, and to a lesser extent, non-acute Hyal2 KO mice (Fig.  8, A-B) , suggesting the accumulation of HA led to the recruitment of macrophages to the lung parenchyma. To confirm that these infiltrating cells were macrophages, we used an antibody toward F4/80 (Fig. 8, M-O) .
Increased HA levels and size in serum and heart of Hyal2 KO mice. A deficiency of HYAL2 had already been demonstrated to lead to increased serum HA (16) . As expected, we found the levels of HA to be approximately 19 fold higher in Hyal2 KO mice compared to controls at 12 weeks (Fig.  9A) . The levels of HA increased with age in the Hyal2 KO mice reaching an average fold increase of 27 at the time of euthanasia (Fig. 9A) . Interestingly, the levels of serum HA were elevated in both acute and non-acute Hyal2 KO animals, indicating that differences in the levels of circulating HA are unlikely to be the cause of the more severe phenotype in acute Hyal2 KO animals.
We also quantified the levels of HA in the heart and lungs of Hyal2 KO mice using FACE. Consistent with the detection of increased HA by immunohistochemistry, elevated levels of HA were found in Hyal2 KO hearts and lungs compared to controls (Fig. 9, B and C) . No significant difference between the levels of HA in non-acute and acute Hyal2 KO mice was detected in the heart (Fig. 7B) . The HA levels also appeared similar in the lungs of acute and non-acute Hyal2 KOs, but our sample size was not large enough for statistical analysis.
We also examined the chondroitin sulphate levels in the heart by FACE, and no significant difference between Hyal2 KO (0.91 ± 0.17ng/mg) and control (0.77 ± 0.12 ng/mg) mice was found (p=0.51, n=4). Given HYAL2's predicted role in initiating the degradation of HA by cleavage of high molecular mass HA to smaller fragments for internalization, we expected that the HA found in the tissues of Hyal2 KO mice would have a larger molecular mass than that in control animals. In order to assess this, HA was partially purified from the serum and hearts of Hyal2 KO and control mice and its size was analyzed by agarose gel electrophoresis. Accumulating HA was clearly evident in the heart (Fig. 9D) and serum (Fig. 9E) of Hyal2 KO mice compared to controls. The size of the HA in Hyal2 KOs was also increased compared to that in control tissues (Fig. 9, D and  E) . The size of the isolated HA did not differ between acute and non-acute Hyal2 KO mice (data not shown). The material that we identified as HA in Fig. 9D and E, was readily digested with hyaluronidase SD, as shown in Fig.9F , verifying its identity. Some of the lower molecular mass bands did not digest with hyaluronidase and are presumably other GAGs or contaminating proteins.
DISCUSSION
This study demonstrates that HYAL2 is essential for cardio-pulmonary function in mice. In its absence, extracellular HA accumulates in the serum and the interstitium of the heart muscle and lungs, heart valves thicken, and pulmonary fibrosis develops in some animals, leading to severe cardio-pulmonary dysfunction and premature death. This cardio-pulmonary failure follows an acute course (mean survival ~3 months) in some animals and a subacute course (mean survival < 6 months) in others. Acutely affected animals exhibited severe atrial dilation, cardiac hypertrophy, and pulmonary fibrosis that were absent from subacute animals. However, increasing plasma HA levels, heart valvulopathy, myocardial infiltration with GAGs and HA, and influx of pulmonary macrophages were present in all Hyal2 KO mice, confirming a major role of HYAL2 in cardio-pulmonary function and possibly in overall HA turnover. Indeed, using the HABP, we have found increased HA levels in most tissues of both acute and non-acute Hyal2 KO mice 2 . Previous examinations of the Hyal2 KO mice had revealed pre-weaning lethality, bone abnormalities, mild anemia, and elevated serum HA (16) .
Whether or not the Hyal2 KO mice develop the more severe acute phenotype is likely determined by other genetic loci. Indeed, the heart phenotype is infrequent on the C57BL/6 background, and the frequency of pre-weaning lethality is lower in the C57BL/6 (<10%) than the outbred background (16%). Taken together, these findings suggest that other loci can strongly influence the phenotype associated with HYAL2 deficiency.
The heart may be especially susceptible to the effects of HYAL2 deficiency because of the high levels of HA in the developing heart (3). In contrast to HA synthase 2 KO mice, where a deficiency of HA synthesis prevents the formation of the endocardial cushion, as well as epithelial to mesenchymal transition (23, 24) , the heart and valves appear to develop normally in Hyal2 KO mice. However, an apparent failure to remove excess HA in the myocardium and valves after their formation, together with a possible ongoing failure of normal HA degradation, leads to postnatal cardio-pulmonary dysfunction.
Heart valvular pathology of the Hyal2 KO mice was not limited to the pulmonary valve, indicating that HYAL2 is important in the homeostasis of valvular ECM in general. This is not surprising given that HA is a major GAG in heart valves and has viscoelastic properties that allow it to absorb shear force during the cardiac cycle (25) . The valvular ECM is expanded and disorganized in various MPSs that result from mutations in GAG degrading enzymes (14, 26) . In addition, similar phenotypes result from defects in some ECM remodelling enzymes, including a deficiency in the ADAMTS 9 enzyme (27) . Abnormalities in HA levels in valves have also been associated with common disorders such as myxomatous valve disease (28) (29) (30) . Given the important role that HYAL2 can play in regulating HA levels, alterations in its level should be considered as a factor that could contribute to valve disease in humans. A complete deficiency of HYAL2 results in a severe phenotype, and therefore it is less likely that a complete deficiency of HYAL2 is compatible with human life.
Mice with HYAL2 deficiency also had excess ECM and accumulating HA in the atrial myocardium. In the acute Hyal2 KO mice there were clearly increased levels of HA although when the level of HA in the total heart was determined, no significant difference between acute and non-acute Hyal2 KOs were detected. It is possible that as the heart attempts to respond to the stress placed on it by abnormal valve function, additional ECM is synthesized, and HA then accumulates. Interestingly, we did not find HA accumulation in the ventricular myocardium, suggesting that Hyal2 deficiency impacts the atrial more than the ventricular myocardium.
HA can make fluids highly viscous and higher plasma viscosity can increase circulatory resistance and induce or aggravate heart failure (31), possibly leading to cardiac hypertrophy and pulmonary edema. This in turn, could result in the accumulation of αSMA and collagen that is seen in the acutely affected Hyal2 KO mice. However we have no pathological evidence for such a chain of events. Although the contribution of elevated serum HA to the phenotype of Hyal2 KO mice is unclear, it is interesting to compare it to the phenotype resulting from a deficiency of a major receptor of HA, the Hyaluronan Receptor for Endocytosis (HARE) (32). Interestingly, Hare KO mice have been reported to show high levels of serum HA, dilated cardiomyopathy, and premature mortality (33). These findings provide further evidence that a disturbance in extracellular HA is responsible for the cardiac phenotype seen in Hyal2 KO mice.
An alternative explanation for the observed lung pathology in acute mice is that a failure to degrade HA results in a primary defect in lung development (34). The smaller size, cardiomyocyte pathology, and atrial dilation in acute Hyal2 KOs could be secondary to impaired lung function. The numerous alveolar and interstitial macrophages in the lungs of Hyal2 KO mice may indicate the attempt to reduce the interstitial deposits of HA and collagen. Such developmental delay could also cause high preweaning lethality in Hyal2 KO mice.
Hyal2 is one of six hyaluronidase genes in humans and seven in mice (35). It is a GPI anchored protein with a neutral pH optimum, and a preference to cleave high molecular mass HA into 20 kDa fragments (1) . Most studies indicate that HYAL2 functions at the cell surface, and therefore has been proposed to degrade extracellular HA to smaller fragments that are internalized for further degradation (36). Our findings support this model as the level of serum HA was extremely high whereas the level of circulating HA has not been shown to be elevated in mouse models with HYAL1 or HYAL3 deficiency. The larger size of the HA that we detected in Hyal2 KO tissues and serum also supports a role for HYAL2 in cleaving HA to smaller fragements for internalization. Further, electron microscopy indicates that the accumulating material in the Hyal2 KO mice is extracellular whereas the material appears to be intracellular in humans that are deficient in HYAL1 (9) . The phenotype observed in Hyal2 KO mice is much more severe than that in the Hyal1 and Hyal3 deficient mice (15, 17) and more similar to that seen in other forms of MPS. This may be due to a redundancy in the intracellular pathway of HA degradation, but no other enzyme that can substitute for HYAL2 in extracellular degradation.
Finally, in 43% of the surviving Hyal2 KO mice we found one kidney was missing. Interestingly, the kidney is another organ that has high levels of HA during development (37), so, like the heart, it may be more susceptible to defects due to HA accumulation. In the longer term, studies of Hyal2 KO mice at different embryonic and pre-weaning stages will help to identify those tissues where HA degradation by HYAL2 is critical.
In conclusion, the present study illustrates the importance of HYAL2 in HA degradation in the heart and in normal cardio-pulmonary function. Localized extracellular accumulation of HA in the KO mice results in a storage disorder which is different from classic MPS disorders where the storage is typically both lysosomal and extracellular. Although a human condition resulting from alterations in HYAL2 activity has not yet been described, it will be interesting to examine the levels of HYAL2 and serum HA concentration in patients with unexplained heart valve abnormalities. Graphed values represent the mean thickness ± SEM. Significant expansion of the valves in Hyal2 KO mice compared to control littermates (n=4, * indicates P < 0.05) was found, but there was no significant difference between non-acute and acute Hyal2 KO mice (n=4, P = 0.60). Calibration bars represent 50 µm. Mean serum HA levels in control, as well as non-acute and acute Hyal2 KO mice at 6 wk (control n=7, non-acute n= 5, acute n=4), 12 wk (control n=6, non-acute n=5, acute n=3), and at death (control n=15, non-acute n=11, acute n=7). The levels of HA in the serum are significantly increased in non-acute and acute Hyal2 KO mice compared to controls. (B) Total HA content in the heart (n=3 in each group). The amount of HA is significantly increased in non-acute and acute Hyal2 KO mice compared to controls but acute and nonacute mice do not differ from one another (P = 0.22). (C) Total HA content in the lung (n= 3 in each group). The amount of HA is significantly increased in the lung of Hyal2 KO compared to control mice (P= 0.04). Graph values expressed as mean ± SEM. Student's t test, *P < 0.05; **P < 0.001; ***P < 0.0001. The control data presented in this figure were from both +/+ and +/-mice. HA size in the heart (D) and serum (E) of Hyal2 KO and control mice was analyzed by agarose gel electrophoresis of GAGs isolated from these tissues. The size of HA standards (Select-HA™ LoLadder; Hyalose) in kDa are shown to the left of the panels. The dark-staining high molecular mass material, spanning the region indicated by the bar to the right of panels D and E, is HA. (F) To differentiate HA within the stained material on the agarose gel from other GAGs and contaminating proteins, GAGs isolated from the serum of control and Hyal2 KO mice were not treated (-) or treated (+) with hyaluronidase and then analyzed by agarose gel electrophoresis. The high molecular mass material was removed by hyaluronidase treatment, identifying it as HA.
